The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line cisplatin-fractionated doublet for unfit patients with advanced/metastatic non-small cell lung cancer.
Giovanni Mansueto
No relevant relationships to disclose
Filomena Narducci
No relevant relationships to disclose
Silvia Quadrini
No relevant relationships to disclose
Maria Laura Mancini
No relevant relationships to disclose
Isabella Sperduti
No relevant relationships to disclose
Teresa Gamucci
No relevant relationships to disclose